Chronic Obstructive Pulmonary Disease News
News on Chronic Obstructive Pulmonary Disease continually updated from thousands of sources around the net.
1 hr ago | Pacific Business Times
The Ventura County Health Care Agency is slated to receive $4.1 million in federal funding to study treatment of chronic obstructive pulmonary disease, or COPD, one of the most common lung conditions in the U.S. The Ventura County Health Care Agency is slated to receive $4.1 million in federal funding to study treatment of chronic obstructive ... (more)
Trending on the Topix Network
6 hrs ago | Chico Enterprise-Record
This July 31, 1964 file photo shows Don Everly and Phil Everly of The Everly Brothers during a performance.
Progressive rehabilitation soon after hospital admission for chronic respiratory disease did not reduce the readmission rate.
Researchers from The Miriam Hospital have found that people with Chronic obstructive pulmonary disease who are also depressed have difficulty sticking to a pulmonary rehabilitation program.
Family members, friends and caregivers are also welcome. July topic: "COPD and Irritants."
Domainex Ltd , a UK-based drug discovery company developing first-in-class small-molecule inhibitors of two closely-related pro-inflammatory kinases - TBK1 and IKK-epsilon , today announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor.
Obese people, particularly those with excess belly fat, may face a higher risk of developing chronic obstructive pulmonary disease , a new study suggests.
There is considerable variability in the susceptibility of smokers to develop chronic obstructive pulmonary disease .
Obesity, especially excessive belly fat, is a risk factor for chronic obstructive pulmonary disease , according to an article in CMAJ Excessive belly fat and low physical activity are linked to progression of the disease in people with COPD, but it is not known whether these modifiable factors are linked to new cases.
Anoro is a once-daily combination treatment comprised of two bronchodilators, umeclidinium , a long-acting muscarinic antagonist , and vilanterol , a long-acting beta2 agonist , in a single inhaler, the Ellipta.
The Japanese Ministry of Health, Labor and Welfare approves GlaxoSmithKline and Theravance's Anoro Ellipta for the relief of various symptoms of chronic obstructive pulmonary diseases in patients who require the concurrent use of a long-acting inhaled muscarinic antagonist and a long-acting inhaled beta2 agonist.
For media outside the US, the UK and Canada. Boehringer Ingelheim today announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the RespimatA Soft Mista Inhaler as a maintenance bronchodilator treatment for patients with chronic obstructive ... (more)
Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date.
Updated: Thu Jul 10, 2014 05:54 pm
Copyright © 2014 Topix LLC